PDGFRB and chordoma: For instance, in patients with PDGFRβ‐positive chordomas, the first and second‐line therapies are tyrosine‐kinase (imatinib) and epidermal growth factor receptor (EGFR) inhibitors (erlotinib), respectively.56, 57